A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Incyte Corp stock. As of the latest transaction made, Fisher Asset Management, LLC holds 11,522 shares of INCY stock, worth $793,174. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,522
Previous 9,258 24.45%
Holding current value
$793,174
Previous $561,000 35.65%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$57.33 - $68.61 $129,795 - $155,333
2,264 Added 24.45%
11,522 $761,000
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $8,495 - $10,582
166 Added 1.83%
9,258 $561,000
Q1 2024

May 09, 2024

SELL
$56.55 - $66.59 $2 Million - $2.35 Million
-35,299 Reduced 79.52%
9,092 $517,000
Q4 2023

Mar 05, 2024

BUY
$52.16 - $64.19 $11,579 - $14,250
222 Added 0.5%
44,391 $2.79 Million
Q4 2023

Feb 06, 2024

BUY
$52.16 - $64.19 $9,753 - $12,003
187 Added 0.43%
44,169 $2.77 Million
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $31,773 - $36,261
550 Added 1.27%
43,982 $2.54 Million
Q2 2023

Dec 12, 2023

SELL
$60.95 - $75.51 $33,522 - $41,530
-550 Reduced 1.25%
43,432 $2.7 Million
Q2 2023

Aug 08, 2023

SELL
$60.95 - $75.51 $9,934 - $12,308
-163 Reduced 0.37%
43,432 $2.7 Million
Q1 2023

Dec 12, 2023

SELL
$70.23 - $86.01 $48,177 - $59,002
-686 Reduced 1.56%
43,296 $3.13 Million
Q1 2023

May 01, 2023

BUY
$70.23 - $86.01 $1,474 - $1,806
21 Added 0.05%
43,595 $3.15 Million
Q4 2022

Feb 03, 2023

BUY
$67.18 - $84.11 $499,886 - $625,862
7,441 Added 20.59%
43,574 $3.5 Million
Q3 2022

Nov 08, 2022

SELL
$66.18 - $82.86 $326,664 - $408,996
-4,936 Reduced 12.02%
36,133 $2.41 Million
Q2 2022

Aug 09, 2022

BUY
$66.18 - $83.18 $299,001 - $375,807
4,518 Added 12.36%
41,069 $3.12 Million
Q1 2022

May 05, 2022

SELL
$66.02 - $79.71 $182,545 - $220,398
-2,765 Reduced 7.03%
36,551 $2.9 Million
Q4 2021

Feb 02, 2022

BUY
$63.34 - $74.11 $28,756 - $33,645
454 Added 1.17%
39,316 $2.89 Million
Q3 2021

Oct 26, 2021

BUY
$68.67 - $84.02 $238,696 - $292,053
3,476 Added 9.82%
38,862 $2.67 Million
Q2 2021

Jul 27, 2021

BUY
$79.87 - $87.53 $48,401 - $53,043
606 Added 1.74%
35,386 $2.98 Million
Q1 2021

Apr 27, 2021

SELL
$76.02 - $100.5 $186,933 - $247,129
-2,459 Reduced 6.6%
34,780 $2.83 Million
Q4 2020

Jan 29, 2021

SELL
$80.74 - $97.7 $62,734 - $75,912
-777 Reduced 2.04%
37,239 $3.24 Million
Q3 2020

Nov 10, 2020

SELL
$85.07 - $109.69 $266,269 - $343,329
-3,130 Reduced 7.61%
38,016 $3.41 Million
Q2 2020

Aug 07, 2020

SELL
$74.18 - $108.93 $667 - $980
-9 Reduced 0.02%
41,146 $4.28 Million
Q1 2020

Apr 28, 2020

SELL
$63.18 - $85.97 $305,728 - $416,008
-4,839 Reduced 10.52%
41,155 $3.01 Million
Q4 2019

Feb 12, 2020

BUY
$73.04 - $95.72 $1.26 Million - $1.66 Million
17,304 Added 60.31%
45,994 $4.02 Million
Q3 2019

Oct 29, 2019

BUY
$72.82 - $86.52 $35,900 - $42,654
493 Added 1.75%
28,690 $2.13 Million
Q2 2019

Jul 30, 2019

SELL
$73.52 - $88.7 $27,275 - $32,907
-371 Reduced 1.3%
28,197 $2.4 Million
Q1 2019

Apr 22, 2019

BUY
$63.56 - $88.17 $219,917 - $305,068
3,460 Added 13.78%
28,568 $2.46 Million
Q4 2018

Jan 25, 2019

BUY
$58.5 - $69.94 $1.11 Million - $1.32 Million
18,925 Added 306.08%
25,108 $1.6 Million
Q3 2018

Oct 24, 2018

SELL
$61.75 - $74.23 $58,045 - $69,776
-940 Reduced 13.2%
6,183 $427,000
Q2 2018

Jul 09, 2018

BUY
$60.85 - $83.98 $62,006 - $85,575
1,019 Added 16.69%
7,123 $477,000
Q1 2018

May 11, 2018

SELL
$83.06 - $100.98 $809,004 - $983,545
-9,740 Reduced 61.47%
6,104 $509,000
Q1 2018

Apr 19, 2018

BUY
$83.06 - $100.98 $180,489 - $219,429
2,173 Added 15.89%
15,844 $1.32 Million
Q4 2017

Jan 24, 2018

SELL
$93.56 - $116.6 $32,839 - $40,926
-351 Reduced 2.5%
13,671 $1.3 Million
Q3 2017

Oct 17, 2017

BUY
$109.15 - $138.27 $1.53 Million - $1.94 Million
14,022
14,022 $1.64 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.